Trial Profile
A Phase Ib/IIa Randomized, Controlled Dose Escalation Study to Evaluate Safety, Tolerability, and Antiviral Activity of BRII-179 (VBI-2601) among Subjects with Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Nov 2021
Price :
$35
*
At a glance
- Drugs VBI 2601 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Proof of concept
- Sponsors Brii Biosciences
- 08 Nov 2021 According to a VBI Vaccines media release, data from this trial were published in JHEP Reports, an open access companion title to Journal of Hepatology in September.
- 26 Jun 2021 Results presented at The International Liver Congress 2021
- 23 Jun 2021 According to a Brii Biosciences media release, Man-Fung Yuen is the principal investigator of the study.